Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PFIZER INC Director's Dealing 2021

Mar 2, 2021

29831_dirs_2021-03-02_29c2d259-bfe9-4df8-a1fc-056d821c2147.zip

Director's Dealing

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2021-02-27

Reporting Person: YOUNG JOHN D (Group President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-02-27 Common Stock M 129419.0000 $22.3500 Acquired 575282.0000 Direct
2021-02-27 Common Stock F 23194.0000 $33.4900 Disposed 552088.0000 Direct
2021-02-27 Common Stock F 82057.0000 $34.6400 Disposed 470031.0000 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-02-27 Stock Appreciation Rights $22.3500 M 129419.0000 Disposed 2021-02-27 Common Stock (129419.0000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 2446.0000 Indirect
Common Stock 1589.0000 Indirect

Footnotes

F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F3: Price is the closing price of Pfizer common stock on February 26, 2021.

F4: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F5: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.